GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

American Oncology Network AONC · USD

Health Care · US listing · 🇺🇸 United States

Compare

22.00

+4.76%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

$1.76bn

FY2020FY2024

Net income

−$4.0m

FY2020FY2024

Free cash flow

−$25.9m

FY2020FY2024

Shareholders' equity

$18.8m

FY2020FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020
Revenue$1.76bn$1.28bn$1.15bn$943.7m$724.7m
Gross profit$117.8m$82.8m$95.5m$78.0m$66.1m
Operating income−$17.4m−$49.2m$5.6m$911,000$22.1m
Net income−$4.0m−$5.5m$2.6m−$105,000$22.0m
Diluted earnings per share-0.29-0.830.06-0.001.63

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020
Total assets$470.3m$374.5m$326.2m$248.3m$49,035
Cash and short-term investments$72.6m$63.9m$36.8m$27.4m$25,000
Total liabilities$362.3m$303.7m$264.2m$22.3m$24,869
Debt$147.4m$128.3m$127.1m$63.7m—
Shareholders' equity$18.8m−$161.7m$62.0m$312.6m$24,166
Shares outstanding13m7m42m42m13m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020
Cash from operations−$4.9m−$18.1m−$6.8m−$1.2m$37.2m
Capital spending−$21.0m−$12.3m−$7.2m−$8.3m−$12.2m
Free cash flow−$25.9m−$30.4m−$14.0m−$9.6m$25.0m

Latest quarters

By quarter end

Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023Sept 2023Jun 2023Mar 2023
Revenue$490.9m$470.3m$434.0m$364.3m$324.2m$336.3m$315.0m$303.7m
Gross profit$42.5m$36.5m$29.4m$9.4m$8.6m$25.4m$23.6m$25.2m
Operating income$8.2m$1.6m−$8.0m−$19.2m−$20.6m−$24.4m−$3.7m−$1.0m
Net income$1.3m−$1.1m$3.6m−$7.8m−$3.8m−$1.8m−$1.7m$179,408
Diluted earnings per share0.10-0.080.27-0.58-0.56-0.27-0.260.03
Cash from operations$11.0m−$28.0m$45.0m$45.0m−$11.0m−$4.0m——
Capital spending−$6.0m−$6.0m−$4.0m−$4.0m−$2.0m−$9.0m−$4.0m−$2.0m
Free cash flow$5.0m−$34.0m$41.0m$41.0m−$13.0m−$13.0m——
Total assets$470.3m$394.8m$430.8m$421.9m$374.5m$394.0m$19.4m$19.2m
Cash and short-term investments$72.6m$19.4m$55.2m$105.0m$63.9m$77.7m$2,044$3,975
Debt$99.3m$100.0m$100.8m$96.7m$96.4m$88.2m$200,000$150,000
Shareholders' equity$18.8m−$38.8m$25.0m−$102.5m−$161.7m−$341.3m$8.5m−$1.0m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue23.1%——
Net income235.7%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin6.6%7.3%——
Operating margin-2.2%-1.2%——
Net margin-0.3%-0.1%——

Valuation history

At each fiscal year end

FY2024
Price to earnings-9.3
Price to sales0.0

Share price return

Finished calendar years

20252024
Return148%254%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 1-to-1 reverse split · 21 Sept 2023

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.